PI3Kδ inhibition hits a sensitive spot in B cell malignancies

Cancer Cell

Volumn 25, Issue 3, 2014, Pages 269-271

  Vanhaesebroeck, Bart ^a   Khwaja, Asim ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IDELALISIB; PLACEBO; RITUXIMAB; B LYMPHOCYTE ANTIGEN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE DELTA; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; UNCLASSIFIED DRUG;

B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; DRUG EFFICACY; DRUG SAFETY; HUMAN; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHORT SURVEY; TUMOR MICROENVIRONMENT; B LYMPHOCYTE; CANCER CELL; CELL ADHESION; DRUG TOLERABILITY; ENZYME INHIBITION; GENE MUTATION; HEMATOLOGIC MALIGNANCY; IMMUNE DEFICIENCY; IMMUNOCOMPETENT CELL; IMMUNOSUPPRESSIVE TREATMENT; INTRACELLULAR SIGNALING; LYMPH NODE; LYMPHOCYTE; LYMPHOID TISSUE; LYMPHOMA; NONHODGKIN LYMPHOMA; SIGNAL TRANSDUCTION; T CELL LEUKEMIA;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; CELL DIFFERENTIATION; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, NON-HODGKIN; PHOSPHATIDYLINOSITOL 3-KINASES; PURINES; QUINAZOLINONES; RECEPTORS, ANTIGEN, B-CELL; SIGNAL TRANSDUCTION;

EID: 84896075568     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2014.02.012     Document Type: Short Survey

References (10)

1. Burger J.A., Montserrat E. Blood 2013, 121:1501-1509.
2. Fruman D.A., Rommel C. Cancer Discov. 2011, 1:562-572.
3. Fruman D.A., Rommel C. Nat. Rev. Drug Discov. 2014, 13:140-156.
4. Furman R.R., Sharman J.P., Coutre S.E., Cheson B.D., Pagel J.M., Hillmen P., Barrientos J.C., Zelenetz A.D., Kipps T.J., Flinn I., et al. N Engl J Med. 2014, Published online January22, 2014. 10.1056/NEJMoa1315226.
5. Gopal A.K., Kahl B.S., de Vos S., Wagner-Johnston N.D., Schuster S.J., Jurczak W.J., Flinn I.W., Flowers C.R., Martin P., Viardot A., et al. N Engl J Med. 2014, Published online January 22, 2014. 10.1056/NEJMoa1314583.
6. Iyengar S., Clear A., Bödör C., Maharaj L., Lee A., Calaminici M., Matthews J., Iqbal S., Auer R., Gribben J., Joel S. Blood 2013, 121:2274-2284.
7. Ji H., Rintelen F., Waltzinger C., Bertschy Meier D., Bilancio A., Pearce W., Hirsch E., Wymann M.P., Rückle T., Camps M., et al. Blood 2007, 110:2940-2947.
8. Ramadani F., Bolland D.J., Garcon F., Emery J.L., Vanhaesebroeck B., Corcoran A.E., Okkenhaug K. Sci. Signal. 2010, 3:ra60.
9. Subramaniam P.S., Whye D.W., Efimenko E., Chen J., Tosello V., De Keersmaecker K., Kashishian A., Thompson M.A., Castillo M., Cordon-Cardo C., et al. Cancer Cell 2012, 21:459-472.
10. Woyach J.A., Smucker K., Smith L.L., Lozanski A., Zhong Y., Ruppert A.S., Lucas D., Williams K., Zhao W., Rasenti L., et al. Blood 2014, Published online January 10, 2014. 10.1182/blood-2013-09-527853.